-
Personnel changes!
Time of Update: 2022-03-08
In recent years, under the influence of policies such as the epidemic, the approaching patent cliff of core products, and the procurement of large quantities, multinational pharmaceutical companies have faced relatively great pressure on their performance, structural adjustments, and frequent personnel changes.
-
Jincheng Pharma's wholly-owned subsidiary Adenosylmethionine butanedisulfonate passed CDE approval
Time of Update: 2022-03-08
Adenosylmethionine is a physiologically active molecule that exists in all tissues and body fluids of the human body.
It is mainly suitable for intrahepatic cholestasis during pregnancy; it is suitable for intrahepatic cholestasis before and caused by liver cirrhosis .
-
2022 Guangzhou Automation Intelligent Packaging Machine Exhibition
Time of Update: 2022-03-08
"2022 Guangzhou International Digital Packaging Exhibition" This exhibition is aimed at the catering industry, food, food processing industry, beverages, dairy products, alcohol, daily chemicals, medicine, products, home appliances, 3C, express delivery, e-commerce, automobiles and other industries Provide intelligent packaging procurement exchange and cooperation trade platform!
-
The first batch of large varieties has been reviewed: Hengrui, Jichuan, Northeast Pharmaceuticals...
Time of Update: 2022-03-08
Since the beginning of the year, many pharmaceutical companies have crossed the line for the first time. Hengrui, Jichuan, and Northeast Pharmaceuticals have entered the market one after another to s
-
2022 Guangzhou Intelligent Anti-counterfeiting and New Label Exhibition
Time of Update: 2022-03-08
According to the current economic development direction, in the next few years, various industries in China Development will move closer to the world's advanced level, keep up with the times, and promote a stronger domestic economy, which will also stimulate market consumption and increase the market demand for intelligent anti-counterfeiting packaging and new label equipment .
-
Food and Drug Administration: A batch of medical devices from Zhongkang Pharmaceutical and Jinyang Bio is being recalled
Time of Update: 2022-03-08
reported that due to possible quality problems in the product, the anti-inflammatory and pain-relieving magnetic therapy patch (registration or record number: Wanxie Zhuhuai 20192090144) produced by it was voluntarily recalled .
-
China's first PD-1 to go overseas is a newborn calf that is not afraid of tigers?
Time of Update: 2022-03-08
On May 18, 2021, Innovent and Eli Lilly jointly announced that the US FDA has officially accepted the PD-1 inhibitor sintilimab injection combined with pemetrexed and platinum for non-squamous non-small cell lung cancer The New Drug Marketing Application (BLA) for the first-line treatment of (NSCLC) is also understood to be a signal of support from the FDA .
-
What is the performance of the blockbuster oncology drugs of multinational pharmaceutical giants?
Time of Update: 2022-03-08
In 2021, O drugs for the first-line treatment of renal cell carcinoma, pleural mesothelioma, and gastric cancer will return to growth momentum, achieving sales revenue of US$7.
Tecentriq's 2021 financial report shows that Roche achieved total revenue of CHF 62.
-
2022 Guangzhou Plastics Processing and Mould Technology Exhibition
Time of Update: 2022-03-08
It adopts a strong global investment promotion mode, integrates the database of previous exhibitions, and mainly invites users in the degradable plastics industry to visit and negotiate .
-
Industry: Local pharmaceutical companies may face big waves when they go overseas!
Time of Update: 2022-03-08
Since zanubrutinib independently developed by BeiGene was approved by the US FDA in November 2019, local innovative drug companies have gradually emerged with enthusiasm for going overseas, and more and more companies have begun to embark on the road of internationalization .
-
The bioreactor is "hot"!
Time of Update: 2022-03-07
Recently, the news of WuXi Biologics being included in the UVL list has aroused the industry's high attention to bioreactors, and the market's expectations for domestic substitution of pharmaceutical equipment have further increased, resulting in some bioreactor-related listed companies even bucking the trend.
-
In 2022, pharmaceutical companies will accelerate drug review
Time of Update: 2022-03-07
In addition, Chenxin Pharmaceutical has also applied for consistency evaluation of 30 varieties (including the declaration of newly registered generic drugs), of which 10 varieties have been over-evaluated.
-
The centralized procurement of orthopedic consumables is here, and enterprises will enter the "low-price era"
Time of Update: 2022-03-07
For example, a few days ago, Beijing Centralized Pharmaceutical Procurement Service Center, Tianjin Pharmaceutical Procurement Center, and Hebei Provincial Centralized Purchase Center of Medical Drugs and Devices officially announced the "Beijing-Tianjin-Hebei "3+N" Alliance Orthopedic Trauma Medical Consumables with Volume Linked Procurement and Use work plan" .
-
Lepu Pharmaceutical's Compound Antihypertensive Drug Valsartan Amlodipine Tablets (Ⅰ) has entered the administrative approval stage
Time of Update: 2022-03-07
com, in 2020, the total sales of valsartan and amlodipine tablets (I) in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) and China's urban physical pharmacy terminals more than 2.
Sales of Valsartan and Amlodipine Tablets (I) in Chinese urban physical pharmacies (unit: ten thousand yuan)Source: Minet.
-
"API + core preparation" walks on both legs West Point Pharmaceuticals landed on the Growth Enterprise Market
Time of Update: 2022-03-07
Market shares of major manufacturers of escitalopram oxalate tablets in my country from 2017 to 2019, source: NMPA Southern InstituteIn the API market field that West Point Pharmaceuticals is involved in, one of the core products - sodium ferulate has a wide range of effects in cardiovascular and cerebrovascular diseases, in the treatment of respiratory diseases, diabetes and its complications, protection of liver and kidneys, etc.
-
Fosun Pharma Holding Subsidiary Cycloserine Capsule Drug Registration Application Accepted
Time of Update: 2022-03-07
According to the latest data from IQVIACHPA, in 2021, the sales of cycloserine capsules in China will be approximately RMB 265 million .
-
Roche/Lilly Oppose US CMS's Draft of Restrictive Medicare Coverage for Biogen Aduhelm
Time of Update: 2022-03-07
Biogen's rivals Roche and Eli Lilly said they would aggressively back the company's struggling Alzheimer's drug Aduhelm, urging the Centers for Medicare and Medicaid Services (CMS) to change Draft restrictive health insurance coverage for this monoclonal antibody .
-
With favorable policies, a large number of enterprises in the pharmaceutical supply chain will usher in a period of opportunity
Time of Update: 2022-03-07
Therefore, with the precipitation of technology research and development by Chinese companies over the years, downstream demand is booming, and national policies continue to guide and support, it is expected that some domestic high-end scientific instruments will also accelerate their rise.
-
Deyuan Pharmaceutical Co., Ltd. has approved batch production of Class 4 Acarbose Tablets and deemed it to have been reviewed
Time of Update: 2022-03-07
On February 10, Deyuan Pharmaceutical, a company listed on the Beijing Stock Exchange, issued an announcement stating that the company's acarbose tablets, which were reported as imitations of Category 4, were batch-produced and deemed to have been reviewed .
-
In the hypoglycemic field, where many heroes compete, domestic pharmaceutical companies are competing for layout
Time of Update: 2022-03-07
It is reported that Hengrui Medicine also recently issued an announcement saying that the Class 1 chemical drug Proline Henggliflozin Tablets has been approved for marketing, becoming my country's currently approved domestic innovative SGLT2 inhibitor.
